Here is the design of a clinical trial:

Official Title: Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)

Included conditions:
- Hemophagocytic Lymphohistiocytosis

Study Armgroups:
- {'label': 'Patients', 'description': '50 patients with sepsis versus 50 patients with HLH \\[anticipated\\]'}

Interventions:

Primary Outcomes:
- {'measure': 'Incidence of HLH in intensive care units based on HLH-2004 criteria', 'description': 'HLH patients are followed up until the end of hospital stay or death.', 'timeFrame': 'Up to 180 days'}

Please estimate the sample size based on the assumption: 
Two-sided 95.0% confidence interval, large sample normal approximation, CI will extend 0.1 from the observed proportion.
Sample size
        The true incidence of adult HLH in ICU is unknown. According to our own research9 and the annual number of patients admitted to our ICU, we expect to see about 200 patients with diagnosed HLH over 2âyears and about 400 with suspected HLH. Of these, we hope to include at least 100 patients with suspected HLH into the study, of whom about 50 patients are expected to be diagnosed with HLH. When the sample size is 100, a two-sided 95.0% CI for a single proportion using the large sample normal approximation will extend 0.1 from the observed proportion for an expected proportion of 0.5 (nQuery Advisor V.7.0).